Your browser is no longer supported. Please, upgrade your browser.
Settings
ICPT Intercept Pharmaceuticals, Inc. daily Stock Chart
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-16.74 Insider Own2.90% Shs Outstand24.83M Perf Week-6.79%
Market Cap2.90B Forward P/E- EPS next Y-12.81 Insider Trans-2.55% Shs Float17.60M Perf Month0.69%
Income-412.80M PEG- EPS next Q-4.27 Inst Own85.70% Short Float32.20% Perf Quarter11.81%
Sales25.00M P/S115.94 EPS this Y-75.20% Inst Trans1.14% Short Ratio10.90 Perf Half Y-31.52%
Book/sh12.69 P/B9.20 EPS next Y21.30% ROA-61.90% Target Price165.31 Perf Year-7.36%
Cash/sh27.76 P/C4.20 EPS next 5Y7.00% ROE-101.00% 52W Range96.63 - 177.93 Perf YTD7.44%
Dividend- P/FCF- EPS past 5Y- ROI-61.30% 52W High-34.40% Beta-2.00
Dividend %- Quick Ratio9.00 Sales past 5Y69.10% Gross Margin- 52W Low20.80% ATR4.95
Employees456 Current Ratio9.00 Sales Q/Q2996.00% Oper. Margin- RSI (14)43.47 Volatility3.79% 3.92%
OptionableYes Debt/Eq1.08 EPS Q/Q-33.60% Profit Margin- Rel Volume0.59 Prev Close115.80
ShortableYes LT Debt/Eq1.08 EarningsFeb 23 BMO Payout- Avg Volume520.02K Price116.73
Recom2.40 SMA20-5.78% SMA50-1.28% SMA200-12.31% Volume305,082 Change0.80%
Jan-20-17Downgrade Needham Buy → Hold
Dec-30-16Reiterated Wedbush Outperform $224
Aug-05-16Downgrade Laidlaw Buy → Sell $345 → $105
Jul-06-16Initiated Cantor Fitzgerald Sell $58
Jun-01-16Reiterated Wedbush Outperform $423 → $239
Apr-08-16Downgrade Morgan Stanley Equal-Weight → Underweight
Apr-05-16Upgrade Wells Fargo Market Perform → Outperform
Mar-30-16Initiated Goldman Neutral
Mar-30-16Initiated Credit Suisse Outperform $200
Feb-24-16Reiterated Wedbush Outperform $493 → $423
Dec-04-15Initiated Wells Fargo Market Perform
Nov-18-15Reiterated Oppenheimer Outperform $375 → $375
Nov-11-15Reiterated FBR Capital Mkt Perform $273 → $192
Oct-28-15Downgrade BofA/Merrill Neutral → Underperform
Aug-13-15Initiated Morgan Stanley Underweight $165
May-21-15Initiated Barclays Overweight $425
May-19-15Downgrade BofA/Merrill Buy → Neutral
Apr-17-15Initiated UBS Buy $465
Mar-17-15Initiated MLV & Co Hold $273
Jan-28-15Reiterated Oppenheimer Outperform $499 → $375
Mar-16-17 04:05PM  Intercept to Present at Upcoming Conference GlobeNewswire
Mar-07-17 01:04PM  INTERCEPT PHARMACEUTICALS INC Financials
11:17AM  These stocks are getting whacked after the GOP unveils its Obamacare replacement
Mar-04-17 06:00AM  Morningstar Runs the Numbers at Morningstar
Mar-03-17 08:15AM  Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for Use in England, Wales and Northern Ireland Accesswire
Mar-02-17 04:30AM  NICE Recommends Ocaliva® (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis in England, Wales and Northern Ireland GlobeNewswire
Mar-01-17 05:08PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Feb-27-17 01:41PM  Intercept Pharmaceuticals, Inc. :ICPT-US: Earnings Analysis: 2016 By the Numbers : February 27, 2017
Feb-24-17 03:37PM  Intercept (ICPT) Q4 Loss Wider than Expected, Revenues Beat
01:21PM  NASH Is Todd Hagopian's Top Biotech Sub-Sector For 2017 at Forbes
12:00AM  Nasdaq Slips as Biotechnology Shares Decline at The Wall Street Journal
Feb-23-17 04:21PM  Nasdaq Slips as Biotechnology Shares Decline at The Wall Street Journal -5.59%
02:16PM  Edited Transcript of ICPT earnings conference call or presentation 23-Feb-17 1:30pm GMT
09:08AM  Intercept (ICPT) Reports a Wider Q4 Loss
08:57AM  Intercept reports 4Q loss
08:11AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors
07:07AM  Q4 2016 Intercept Pharmaceuticals Inc Earnings Release - Before Market Open
07:05AM  Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update GlobeNewswire
Feb-22-17 08:29AM  Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More
Feb-21-17 06:30PM  Intercept (ICPT) to Post Q4 Earnings: What's in the Cards?
Feb-18-17 08:23AM  Investors Are Betting Big Against Intercept Pharmaceuticals. Are They Wrong? at Motley Fool
Feb-17-17 07:05AM  Intercept to Report 2016 Full Year Financial Results on February 23 and Present at Upcoming Conferences GlobeNewswire
Feb-14-17 10:16AM  Intercept Spikes on Liver Drug Study Redesign at Investopedia
Feb-13-17 11:47AM  Analysts Split On How To Read Intercept Switching Clinical Trial Endpoints
Feb-12-17 12:07PM  Why Intercept Pharmaceuticals' Latest News Caused the Stock to Jump at Motley Fool
Feb-10-17 09:00PM  Full Speed Ahead; Big Moves: Best of Kass +5.16%
04:10PM  Intercept Bounds To 3-Month High On NASH Trial Edits; Analysts Split
02:57PM  What's With Wall Street's Lofty Price Targets On Intercept?
11:20AM  Why Shares Of Intercept Pharma Are Soaring Today at Barrons.com
10:07AM  Intercept Pharma: We Can't Enroll Our NASH Study so We're Changing the Study. Trust Us, All Good
07:00AM  Intercept to Provide Update on Phase 3 REGENERATE Trial of Obeticholic Acid for the Treatment of NASH Patients with Liver Fibrosis GlobeNewswire
Jan-24-17 08:13AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : January 24, 2017
Jan-22-17 01:27PM  3 Biotechs Likely to Be Acquired in 2017 at Motley Fool
Jan-20-17 07:35AM  Intercept Pharma downgraded by Needham
Jan-18-17 02:05PM  Intercept Pharmaceuticals, Inc. Value Analysis (NASDAQ:ICPT) : January 18, 2017
12:37PM  Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug
Jan-17-17 05:13PM  Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?
12:11PM  ETFs with exposure to Intercept Pharmaceuticals, Inc. : January 17, 2017
Jan-15-17 11:56AM  Should Investors Bet on Gilead Sciences Version 3.0? at Motley Fool
Jan-13-17 07:23AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US : January 13, 2017
Jan-10-17 12:59PM  Todd Hagopian's Top Biotech Takeover Targets For 2017 at Forbes
Jan-08-17 11:43AM  3 Companies Whose Sales Could Double in 2017 at Motley Fool
Jan-05-17 08:30AM  Are M&A Rumors Driving Intercept Pharma's Stock? at Investopedia
Jan-04-17 04:05PM  Intercept to Present at Upcoming Investor Conference GlobeNewswire +5.62%
11:06AM  ETFs with exposure to Intercept Pharmaceuticals, Inc. : January 4, 2017
Dec-30-16 08:25AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : December 30, 2016
Dec-29-16 08:45AM  Intercept Pharmaceuticals (ICPT) Jumps: Stock Rises 9.3%
Dec-28-16 05:14PM  Why Sandstorm Gold, Weis Markets, and Intercept Pharmaceuticals Jumped Today at Motley Fool +9.34%
Dec-22-16 05:52PM  Biotech buying opportunity?
Dec-20-16 10:30AM  Conatus Pharma Doubles On Novartis NASH Liver Drug Licensing Deal
Dec-17-16 07:35AM  Could These 2 Small Biotechs Beat Allergan and Gilead Sciences? at Motley Fool
Dec-16-16 01:51PM  ETFs with exposure to Intercept Pharmaceuticals, Inc. : December 16, 2016
12:04PM  5 Stocks That Could Make You Rich at Motley Fool
Dec-15-16 08:58AM  Intercept (ICPT) Ocaliva Gains Conditional Approval in EU
08:30AM  Blog Coverage Intercept Pharma Receives European Approval for the Treatment of a Rare Liver Condition Accesswire
Dec-14-16 07:16AM  Intercept Pharma's liver drug wins conditional EU approval
07:01AM  European Commission Grants Intercept's Ocaliva® (obeticholic acid) Marketing Authorization for the Treatment of Primary Biliary Cholangitis GlobeNewswire
07:00AM  European Commission Grants Intercepts Ocaliva® (obeticholic acid) Marketing Authorization for the Treatment of Primary Biliary Cholangitis GlobeNewswire
Dec-09-16 05:00PM  Intercept to Present at Upcoming Investor Conference GlobeNewswire
07:01AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi
Dec-05-16 01:05PM  10 Major Pharma and FDA Catalysts Coming in December at 24/7 Wall St.
03:05AM  Intercept Pharmaceuticals Inc (ICPT): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-30-16 12:27PM  ETFs with exposure to Intercept Pharmaceuticals, Inc. : November 30, 2016
Nov-17-16 06:59AM  3 Potential Acquisition Targets for Gilead Sciences, Inc. at Motley Fool
Nov-16-16 01:12PM  ETFs with exposure to Intercept Pharmaceuticals, Inc. : November 16, 2016
Nov-14-16 10:19AM  Intercept Pharmaceuticals, Inc. :ICPT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
Nov-11-16 08:00AM  Intercept Presents New Data at AASLD Examining the Effects of Ocaliva® (Obeticholic Acid) on Non-Invasive Assessments of Liver Fibrosis in Patients with PBC GlobeNewswire
Nov-09-16 05:09PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report +14.80%
Nov-04-16 09:35AM  Intercept (ICPT) Q3 Loss Narrower than Expected, Sales Miss
Nov-03-16 06:08PM  Edited Transcript of ICPT earnings conference call or presentation 3-Nov-16 12:30pm GMT -16.46%
09:46AM  Intercept reports 3Q loss
08:56AM  Intercept (ICPT) Reports Narrower-Than-Expected Q3 Loss
08:01AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:07AM  Q3 2016 Intercept Pharmaceuticals Inc Earnings Release - Before Market Open
07:05AM  Intercept Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update GlobeNewswire
Nov-02-16 04:28PM  Gilead Cuts Losses On NASH Drug, But Liver Is 'Area Of Opportunity'
08:03AM  Drug Stocks Q3 Earnings Roster for Nov 3; ICPT, EXEL, AKRX
Nov-01-16 08:07AM  Intercept (ICPT) Q3 Earnings Preview: What's in the Cards?
07:05AM  Intercept Announces Ocaliva® (Obeticholic Acid) Data in PBC to be Presented at the 2016 AASLD Annual Meeting GlobeNewswire
Oct-31-16 10:04AM  $40 Billion Opportunity: 3 Biotechs Poised to Dominate at Motley Fool
Oct-28-16 04:05PM  Intercept to Report Third Quarter 2016 Financial Results on November 3 GlobeNewswire
Oct-21-16 04:03PM  Gilead NASH Drug 'Active And Promising,' But Lagging Intercept
12:34PM  Gilead Sciences: These Things Take Time at Barrons.com
Oct-20-16 12:24PM  Gilead Sciences Advances Fatty Liver Drug, Causing Some Head-Scratching
08:54AM  Vertex (VRTX) Q3 Earnings: What's in Store for the Stock?
Oct-17-16 09:53AM  Intercept (ICPT) Ocaliva Wins Positive CHMP Opinion for PBC
Oct-14-16 12:39PM  Intercept Liver Drug Gets Conditional EU OK (ICPT) at Investopedia
07:36AM  Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva® (Obeticholic Acid) for the... GlobeNewswire
07:35AM  Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva® (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union GlobeNewswire
Oct-13-16 05:22PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
08:04AM  In Depth Review of Gilead Sciences NASH Pipeline Opportunities
Oct-11-16 04:18PM  Allergan Challenges Intercept With Tobira NASH Drug
Oct-05-16 08:04AM  Allergan Enters the Attractive NASH Market
Oct-04-16 04:23PM  Which Biotechs Set Up For Q4 Boost From Drug Trial Results? -5.77%
11:04AM  Understanding Gilead Sciences NASH Pipeline
Oct-03-16 08:19AM  Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ICPT-US : October 3, 2016
Sep-22-16 11:15PM  Intercept Pharmaceuticals Inc (ICPT) CEO & President Mark Pruzanski Sold $5.8 million of Shares
04:35PM  Gilead, Allergan Seen Trailing Intercept In Ongoing NASH Battle
10:32AM  Gilead Sciences: A Hidden Asset? at Barrons.com
09:08AM  5 Biotech Stocks to Watch as Interest in NASH Increases
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bright LisaPresident InternationalMar 02Sale130.161,313170,90323,314Mar 06 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentMar 01Option Exercise21.501,35029,02547,719Mar 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentMar 01Sale128.661,350173,69146,369Mar 03 09:01 PM
Bright LisaPresident InternationalMar 01Sale130.1613617,70221,813Mar 03 09:00 PM
Bright LisaPresident InternationalFeb 27Sale119.4825430,34821,695Mar 01 09:00 PM
Bright LisaPresident InternationalJan 31Sale108.9613414,60117,249Feb 02 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJan 09Sale106.011,565165,90640,369Jan 11 09:00 PM
Bright LisaPresident InternationalJan 03Sale103.921,119116,28517,090Jan 05 09:01 PM
Pruzanski MarkCEO & PresidentJan 03Sale103.922,802291,181552,705Jan 05 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJan 03Sale103.92988102,67241,934Jan 05 09:01 PM
McMinn RachelChief Strategy OfficerJan 03Sale103.9281684,79812,916Jan 05 09:00 PM
Pruzanski MarkCEO & PresidentDec 06Option Exercise28.673,48799,983555,507Dec 08 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentDec 02Sale99.751,350134,66342,922Dec 06 09:00 PM
Bright LisaPresident InternationalNov 25Sale113.6024928,28618,209Nov 29 09:00 PM
Bright LisaPresident InternationalNov 15Sale112.2714015,71818,458Nov 17 09:39 PM
McMinn RachelChief Strategy OfficerOct 31Sale123.8212915,97213,732Nov 02 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentOct 10Sale153.3441163,02344,272Oct 12 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentOct 03Option Exercise21.501,35029,02546,196Oct 05 09:06 PM
Pruzanski MarkCEO & PresidentOct 03Sale163.20705115,056552,020Oct 05 09:07 PM
Shapiro DavidCMO and EVP - DevelopmentOct 03Sale163.081,513246,73344,683Oct 05 09:06 PM
Duncan Barbara GayleChief Accounting OfficerOct 03Sale163.2014723,99030,661Oct 05 09:04 PM
Bright LisaSee RemarksOct 03Sale163.2015525,29618,305Oct 05 09:02 PM
Shapiro DavidCMO and EVP - DevelopmentSep 26Sale165.083,545585,20044,846Sep 28 09:00 PM
Pruzanski MarkCEO & PresidentSep 20Option Exercise8.9435,000313,054587,725Sep 22 09:00 PM
Pruzanski MarkCEO & PresidentSep 20Sale165.0035,0005,775,000552,725Sep 22 09:00 PM
Bright LisaPresident of InternationalAug 25Sale159.0024639,11418,460Aug 25 09:00 PM
McMinn RachelChief Strategy OfficerAug 01Sale176.5712522,07113,861Aug 02 09:00 PM
Pruzanski MarkCEO & PresidentJul 15Option Exercise9.8212,500122,779560,066Jul 19 09:00 PM
Duncan Barbara GayleChief Accounting OfficerJul 05Sale145.1114621,18630,808Jul 07 09:03 PM
McMinn RachelChief Strategy OfficerJul 05Sale145.1110615,38213,986Jul 07 09:01 PM
Pruzanski MarkCEO & PresidentJul 05Sale145.11714103,608547,566Jul 07 09:02 PM
Bright LisaSee RemarksJul 05Sale145.1115522,49218,706Jul 07 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 05Sale145.1116323,65348,391Jul 07 09:02 PM
Bright LisaSee RemarksMay 25Sale137.5025134,51218,855May 26 09:00 PM
McMinn RachelChief Strategy OfficerMay 02Sale147.4913019,17414,087May 04 09:00 PM
Pruzanski MarkCEO & PresidentApr 04Sale130.7670892,578548,248Apr 06 09:02 PM
Shapiro DavidCMO and EVP - DevelopmentApr 04Sale130.7616521,57548,546Apr 06 09:02 PM
McMinn RachelChief Strategy OfficerApr 04Sale130.7610413,59914,217Apr 06 09:01 PM
Bright LisaSee RemarksApr 04Sale130.7615320,00619,106Apr 06 09:01 PM
Duncan Barbara GayleChief Financial OfficerApr 04Sale130.7614418,82930,948Apr 06 09:00 PM